STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARDX
  4. [Form 4] Ardelyx, Inc. Insider Trading Activity

Ardelyx Form 4: Chief Patient Officer sells 6,261 shares via sell-to-cover

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Laura A. Williams, listed as Chief Patient Officer and a director of Ardelyx, Inc. (ARDX), reported a non-derivative sale on 08/21/2025. The filing shows 6,261 shares of common stock were sold at $5.9317 per share under code S(1). The sale was executed pursuant to an automatic sell-to-cover tied to the vesting of restricted stock units to cover withholding taxes. After the transaction, Williams is reported to beneficially own 396,322 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025.

Positive

  • Transaction documented and compliant with Section 16 reporting and shows use of automatic sell-to-cover for RSU tax withholding

Negative

  • None.

Insights

TL;DR: Routine sell-to-cover of vested RSUs indicates standard tax withholding, not a discretionary sale by the reporting officer.

The Form 4 documents an automatic sell-to-cover related to RSU vesting, which is a common administrative action to satisfy tax withholding obligations. The transaction code S(1) and the filing note clarify the shares were sold solely to cover taxes rather than for liquidity or trading purposes. The reported remaining beneficial ownership of 396,322 shares provides context for the officer's stake but does not alone imply a change in control or material shift in alignment with shareholders.

TL;DR: Small, routine disposal; transaction size is immaterial relative to typical insider holdings and company market cap.

The sale of 6,261 shares at $5.9317 per share is explicitly described as automatic sell-to-cover on RSU vesting. Such transactions are administrative and typically categorized as neutral for valuation or governance assessments. The remaining beneficial ownership figure is stated, enabling tracking of insider holdings over time. No derivative transactions or additional dispositions are reported in this filing.

Insider Williams Laura A
Role Chief Patient Officer
Sold 6,261 shs ($37K)
Type Security Shares Price Value
Sale Common Stock 6,261 $5.9317 $37K
Holdings After Transaction: Common Stock — 396,322 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Williams Laura A
(Last) (First) (Middle)
C/O ARDELYX, INC.
400 FIFTH AVENUE, SUITE 210
(Street)
WALTHAM MA 02451
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARDELYX, INC. [ ARDX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Patient Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/21/2025 S(1) 6,261 D $5.9317 396,322 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
Remarks:
/s/ Elizabeth Grammer, Attorney-in-Fact for Laura A. Williams 08/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Laura A. Williams report on Form 4 for ARDX?

The filing reports a sale of 6,261 shares of ARDX common stock on 08/21/2025 at $5.9317 per share.

Why were the ARDX shares sold by the reporting person?

The shares were sold pursuant to an automatic sell-to-cover triggered by the vesting of restricted stock units to cover applicable withholding taxes.

How many ARDX shares does Laura A. Williams beneficially own after the transaction?

The Form 4 reports 396,322 shares beneficially owned following the reported sale.

Who signed the Form 4 for Laura A. Williams and when was it signed?

The Form 4 was signed by Elizabeth Grammer, Attorney-in-Fact for Laura A. Williams on 08/25/2025.

Was this Form 4 filed by one reporting person or multiple filers?

The filing indicates it was a Form filed by one reporting person.